Compared to past years, the FDA seems to be moving with lightning speed. ImmunoDigest.com’s mission is to provide cancer patients, and their advocates, with relevant, current and easy-to-understand information. There have been four more oncology approvals in the last few days. Three of them have been for types of lymphoma. Anyone with any of these types of cancer should discuss these FDA approvals with their oncologist to learn if they would be recommended as treatments. As with all therapies, there are conditions to be met and your oncologist is the best person to tell you more.
  1. Alectinib approved for ALK (anaplastic lymphoma kinase) positive metastatic non-small cell lung cancer
  2. Acalabrutinib for mantle cell lyphoma
  3. Brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma approved for positive metastatic non-small cell lung cancer.
Another approval was for an orphan drug known as vemurafenib for Erdheim-Chester Disease. If this is your diagnosis consult with your oncologist as soon as possible. We hope this information will help some of our subscribers!